Drug Discovery World
JANUARY 16, 2024
Professor Helen McShane, Chief Investigator, TB Vaccine Trials Jenner Institute, University of Oxford, said: “TB kills more people than any other infectious disease and we urgently need better vaccines. The post Clinical trial will test novel inhaled TB vaccine appeared first on Drug Discovery World (DDW).
Pharmaceutical Technology
MAY 22, 2023
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted an investigational new drug application (IND) for SinoMab BioScience’s SM17 to treat asthma. It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Scienmag
JANUARY 26, 2022
WHAT: In adults who had previously received a full regimen of any of three COVID-19 vaccines granted Emergency Use Authorization (EUA) or approved by the Food and Drug Administration (FDA), an additional booster dose of any of these vaccines was safe and prompted an immune response, according to preliminary clinical trial results reported in The […]. (..)
pharmaphorum
JUNE 30, 2021
Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune responses in a phase 1 trial. . The post Altimmune ditches nasal COVID vaccine on weak trial data appeared first on.
Drug Discovery World
APRIL 26, 2024
A clinical trial of a personalised mRNA cancer vaccine for melanoma patients has been launched in the UK. The post “Game-changing” personalised cancer vaccine enters UK clinical trials appeared first on Drug Discovery World (DDW). in the combination arm and 62.2%
Drug Discovery World
SEPTEMBER 15, 2023
Replicate Bioscience has dosed the first participant in a Phase I trial of its RBI-4000 vaccine for the prevention of rabies. Replicate’s srRNA technology offers the potential for more robust and durable immune responses, and improved tolerability at lower doses than existing mRNA approaches,” said Zelanna Goldberg, CMO of Replicate. “In
Pharmaceutical Technology
NOVEMBER 11, 2022
The vaccine elicited a robust immune response against several variants in registrational trials conducted when the Omicron variant of the virus was dominant. These trials comprised the Phase III VAT08 Stage 2 trial analysing initial efficacy and two other immunogenicity trials.
Expert insights. Personalized for you.
59 
Let's personalize your content